You can buy or sell Advaxis and other stocks, options, ETFs, and crypto commission-free!
Advaxis, Inc. Common Stock, also called Advaxis, is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. Read More It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Princeton, New Jersey
52 Week High
52 Week Low
Has Advaxis (ADXS) Outpaced Other Medical Stocks This Year?
ONE Gas (OGS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Investors focused on the Medical space have likely heard of Advaxis (ADXS), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out. Advaxis is one of 833 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges...
Yahoo FinanceMar 13
These Four Healthcare Stocks Are Making Moves on Wednesday
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry.
Yahoo FinanceMar 12
Advaxis: Fiscal 1Q Earnings Snapshot
PRINCETON, N.J. (AP) _ Advaxis Inc. (ADXS) on Tuesday reported fiscal first-quarter net income of $12.8 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Princeton, New Jersey-based company said it had profit of 18 cents. Earnings, adjusted for non-recurring gains, came to 15 cents per share. The biotechnology company posted revenue of $19.7 million in the period. The company's shares closed at 33 cents. A year ago, they were trading at $2.20. _____ This story...
-$0.25 per share
-$0.04 per share